Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes

Philip Raskin, Julio Rosenstock, Patricia Challis, Steven Ryder, John F. Mullane, Ramona Gonzalez, David Hicks, Theodore Smith, Dushan Dvornik

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effect of the aldose reductase inhibitor, tolrestat, on red blood cell (RBC) sorbitol levels was studied in 23 patients with diabetes after oral dosing with tolrestat, 25 or 100 mg b.i.d. The mean (± SE) RBC sorbitol levels (measured 12 hours after the preceding dose) after 3, 7, and 13 days of dosing decreased after both dose levels. After 25 mg tolrestat the RBC sorbitol levels fell from 25.1 ± 4.0 to 20.0 ± 5.7 nmol/gm hemoglobin (21%) and after 100 mg tolrestat the level fell from 26.7 ± 3.7 to 11.4 1.7 nmol/gm hemoglobin (57%; P < 0.001). This latter RBC sorbitol concentration is similar to levels in individuals without diabetes. At both dosage levels the maximum decrease in RBC sorbitol levels occurred after only 3 days of dosing. Tolrestat had no effect on plasma glucose or hemoglobin A, concentrations. The overall mean plasma unbound drug concentration measured 12 hours after 100 mg tolrestat (11.7 ± 3.0 ng/ml; 3.3 × 10-8 mol/L) was similar to the median inhibitory level (3 × 10-8 mol/L) of tolrestat for sorbitol accumulation in human RBCs incubated in a high-glucose medium. Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes.

Original languageEnglish (US)
Pages (from-to)625-630
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume38
Issue number6
StatePublished - Dec 1985

Fingerprint

Sorbitol
Erythrocytes
Aldehyde Reductase
Hemoglobin A
Glucose
tolrestat
Biological Availability
Hemoglobins
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Raskin, P., Rosenstock, J., Challis, P., Ryder, S., Mullane, J. F., Gonzalez, R., ... Dvornik, D. (1985). Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clinical Pharmacology and Therapeutics, 38(6), 625-630.

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. / Raskin, Philip; Rosenstock, Julio; Challis, Patricia; Ryder, Steven; Mullane, John F.; Gonzalez, Ramona; Hicks, David; Smith, Theodore; Dvornik, Dushan.

In: Clinical Pharmacology and Therapeutics, Vol. 38, No. 6, 12.1985, p. 625-630.

Research output: Contribution to journalArticle

Raskin, P, Rosenstock, J, Challis, P, Ryder, S, Mullane, JF, Gonzalez, R, Hicks, D, Smith, T & Dvornik, D 1985, 'Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes', Clinical Pharmacology and Therapeutics, vol. 38, no. 6, pp. 625-630.
Raskin P, Rosenstock J, Challis P, Ryder S, Mullane JF, Gonzalez R et al. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clinical Pharmacology and Therapeutics. 1985 Dec;38(6):625-630.
Raskin, Philip ; Rosenstock, Julio ; Challis, Patricia ; Ryder, Steven ; Mullane, John F. ; Gonzalez, Ramona ; Hicks, David ; Smith, Theodore ; Dvornik, Dushan. / Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. In: Clinical Pharmacology and Therapeutics. 1985 ; Vol. 38, No. 6. pp. 625-630.
@article{7392e588e5274677be649696e4494e38,
title = "Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes",
abstract = "The effect of the aldose reductase inhibitor, tolrestat, on red blood cell (RBC) sorbitol levels was studied in 23 patients with diabetes after oral dosing with tolrestat, 25 or 100 mg b.i.d. The mean (± SE) RBC sorbitol levels (measured 12 hours after the preceding dose) after 3, 7, and 13 days of dosing decreased after both dose levels. After 25 mg tolrestat the RBC sorbitol levels fell from 25.1 ± 4.0 to 20.0 ± 5.7 nmol/gm hemoglobin (21{\%}) and after 100 mg tolrestat the level fell from 26.7 ± 3.7 to 11.4 1.7 nmol/gm hemoglobin (57{\%}; P < 0.001). This latter RBC sorbitol concentration is similar to levels in individuals without diabetes. At both dosage levels the maximum decrease in RBC sorbitol levels occurred after only 3 days of dosing. Tolrestat had no effect on plasma glucose or hemoglobin A, concentrations. The overall mean plasma unbound drug concentration measured 12 hours after 100 mg tolrestat (11.7 ± 3.0 ng/ml; 3.3 × 10-8 mol/L) was similar to the median inhibitory level (3 × 10-8 mol/L) of tolrestat for sorbitol accumulation in human RBCs incubated in a high-glucose medium. Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes.",
author = "Philip Raskin and Julio Rosenstock and Patricia Challis and Steven Ryder and Mullane, {John F.} and Ramona Gonzalez and David Hicks and Theodore Smith and Dushan Dvornik",
year = "1985",
month = "12",
language = "English (US)",
volume = "38",
pages = "625--630",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes

AU - Raskin, Philip

AU - Rosenstock, Julio

AU - Challis, Patricia

AU - Ryder, Steven

AU - Mullane, John F.

AU - Gonzalez, Ramona

AU - Hicks, David

AU - Smith, Theodore

AU - Dvornik, Dushan

PY - 1985/12

Y1 - 1985/12

N2 - The effect of the aldose reductase inhibitor, tolrestat, on red blood cell (RBC) sorbitol levels was studied in 23 patients with diabetes after oral dosing with tolrestat, 25 or 100 mg b.i.d. The mean (± SE) RBC sorbitol levels (measured 12 hours after the preceding dose) after 3, 7, and 13 days of dosing decreased after both dose levels. After 25 mg tolrestat the RBC sorbitol levels fell from 25.1 ± 4.0 to 20.0 ± 5.7 nmol/gm hemoglobin (21%) and after 100 mg tolrestat the level fell from 26.7 ± 3.7 to 11.4 1.7 nmol/gm hemoglobin (57%; P < 0.001). This latter RBC sorbitol concentration is similar to levels in individuals without diabetes. At both dosage levels the maximum decrease in RBC sorbitol levels occurred after only 3 days of dosing. Tolrestat had no effect on plasma glucose or hemoglobin A, concentrations. The overall mean plasma unbound drug concentration measured 12 hours after 100 mg tolrestat (11.7 ± 3.0 ng/ml; 3.3 × 10-8 mol/L) was similar to the median inhibitory level (3 × 10-8 mol/L) of tolrestat for sorbitol accumulation in human RBCs incubated in a high-glucose medium. Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes.

AB - The effect of the aldose reductase inhibitor, tolrestat, on red blood cell (RBC) sorbitol levels was studied in 23 patients with diabetes after oral dosing with tolrestat, 25 or 100 mg b.i.d. The mean (± SE) RBC sorbitol levels (measured 12 hours after the preceding dose) after 3, 7, and 13 days of dosing decreased after both dose levels. After 25 mg tolrestat the RBC sorbitol levels fell from 25.1 ± 4.0 to 20.0 ± 5.7 nmol/gm hemoglobin (21%) and after 100 mg tolrestat the level fell from 26.7 ± 3.7 to 11.4 1.7 nmol/gm hemoglobin (57%; P < 0.001). This latter RBC sorbitol concentration is similar to levels in individuals without diabetes. At both dosage levels the maximum decrease in RBC sorbitol levels occurred after only 3 days of dosing. Tolrestat had no effect on plasma glucose or hemoglobin A, concentrations. The overall mean plasma unbound drug concentration measured 12 hours after 100 mg tolrestat (11.7 ± 3.0 ng/ml; 3.3 × 10-8 mol/L) was similar to the median inhibitory level (3 × 10-8 mol/L) of tolrestat for sorbitol accumulation in human RBCs incubated in a high-glucose medium. Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0022339291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022339291&partnerID=8YFLogxK

M3 - Article

C2 - 4064465

AN - SCOPUS:0022339291

VL - 38

SP - 625

EP - 630

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -